Cardiol Therapeutics Inc.
CRDL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001702123
No open-market purchases or sales by Cardiol Therapeutics Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $31.3M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Cardiol Therapeutics Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 28 | 27 | −1 |
| Shares | 6.24M | 5.72M | −528.0K (−8.5%) |
| Value | $8.58M | $6.25M | −$2.33M (−27.2%) |
New holders (4)
Institutions that held Cardiol Therapeutics Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 34,543 | $36.0K | 0.00% |
| Bank of Montreal | 14,731 | $15.0K | 0.00% |
| Benjamin Edwards Inc | 875 | $1.00K | 0.00% |
| Rise Advisors, LLC | 1,000 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Cardiol Therapeutics Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Brookstone Capital Management | 15,025 | $20.0K |
| LPL Financial LLC | 10,230 | $14.0K |
| Simplex Trading, LLC | 8,365 | $11.0K |
| Citigroup Inc | 792 | $1.00K |
| BlackRock Inc. | 40 | $0 |